echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Innovative combination of RNA activation therapy for first-line treatment of advanced liver cancer enters the clinic

    Innovative combination of RNA activation therapy for first-line treatment of advanced liver cancer enters the clinic

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On December 1, 2021, the Cancer Institute of the National University of Singapore (NCIS) and MiNA Therapeutics jointly announced that MiNA's small-activated RNA therapy MTL-CEBPA, combined with standard treatments atezolizumab and bevacizumab (bevacizumab), is the first-line treatment for advanced liver The phase 1 clinical trial for patients with cell carcinoma (HCC) has completed the first patient's administration
    Atezolizumab is a PD-L1 inhibitor.
    The combination of treatment with anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is the first first-line immunotherapy for liver cancer approved by the FDA


    Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths worldwide
    According to statistics, more than 750,000 people worldwide suffer from hepatocellular carcinoma each year, most of which occur in Asia, and almost half of the cases are in China

    The main causes of HCC are chronic hepatitis caused by hepatitis B or C virus infection, and liver cirrhosis caused by drinking or non-alcoholic steatohepatitis


    The phenomenon that can specifically up-regulate targeted genes is called RNA activation (RNAa), and those small double-stranded RNAs with RNAa function are called small activating RNA (saRNA)
    The chemical structure of saRNA is similar to siRNA, it recruits the endogenous transcription complex to the target gene, resulting in increased mRNA expression and up-regulation of target protein expression


    The press release pointed out that MTL-CEBPA is the first therapy to specifically upregulate CCAAT/enhancer binding protein alpha (C/EBP-α).
    CCAAT/enhancer binding protein alpha is a transcription factor that determines the lineage of myeloid cells.
    The main regulator of differentiation

    Disorders of myeloid cells are related to many diseases

    MTL-CEBPA aims to restore the C/EBP-α protein to normal levels through the RNA activation mechanism and reduce the immunosuppressive effect of myeloid cells

    It is composed of double-stranded RNA encapsulated by liposomal nanoparticles

    In preclinical studies, it has been proven that MTL-CEBPA can improve the anti-tumor activity of cancer treatment by targeting dysregulated myeloid cells and reducing their inhibitory effect in the tumor microenvironment


    The open-label Phase 1 trial will enroll approximately 30 patients with unresectable or advanced HCC who have not received systemic therapy in the past
    The main purpose of the dose escalation phase is to determine dose-limiting toxicity, and the primary end point of the dose extension phase is the patient’s objective response rate (ORR)

    The trial is expected to obtain data in 2023


    Reference materials:

    [1] National University Cancer Institute, Singapore and MiNA Therapeutics Announce Initiation of a Phase 1 Clinical Study of MTL-CEBPA in Combination With First-line Standard of Care in Advanced Liver Cancer.
    Retrieved December 1, 2021, from https://www .

    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.